Matches in Wikidata for { <http://www.wikidata.org/entity/Q58088022> ?p ?o ?g. }
Showing items 1 to 70 of
70
with 100 items per page.
- Q58088022 description "im Oktober 2018 veröffentlichter wissenschaftlicher Artikel" @default.
- Q58088022 description "scholarly article by Lionel Ades et al published 31 October 2018 in Haematologica" @default.
- Q58088022 description "wetenschappelijk artikel" @default.
- Q58088022 description "наукова стаття, опублікована в жовтні 2018" @default.
- Q58088022 name "A phase II study of the efficacy and safety of an intensified schedule of azacitidine in intermediate-2 and high risk patients with myelodysplastic syndromes: a study by the Groupe Francophone des myelodysplasies (GFM)" @default.
- Q58088022 name "A phase II study of the efficacy and safety of an intensified schedule of azacitidine in intermediate-2 and high risk patients with myelodysplastic syndromes: a study by the Groupe Francophone des myelodysplasies" @default.
- Q58088022 type Item @default.
- Q58088022 label "A phase II study of the efficacy and safety of an intensified schedule of azacitidine in intermediate-2 and high risk patients with myelodysplastic syndromes: a study by the Groupe Francophone des myelodysplasies (GFM)" @default.
- Q58088022 label "A phase II study of the efficacy and safety of an intensified schedule of azacitidine in intermediate-2 and high risk patients with myelodysplastic syndromes: a study by the Groupe Francophone des myelodysplasies" @default.
- Q58088022 altLabel "A phase II study of the efficacy and safety of an intensified schedule of azacytidine in intermediate-2 and high-risk patients with myelodysplastic syndromes: a study by the Groupe Francophone des Myelodysplasies (GFM)" @default.
- Q58088022 prefLabel "A phase II study of the efficacy and safety of an intensified schedule of azacitidine in intermediate-2 and high risk patients with myelodysplastic syndromes: a study by the Groupe Francophone des myelodysplasies (GFM)" @default.
- Q58088022 prefLabel "A phase II study of the efficacy and safety of an intensified schedule of azacitidine in intermediate-2 and high risk patients with myelodysplastic syndromes: a study by the Groupe Francophone des myelodysplasies" @default.
- Q58088022 P1433 Q58088022-284C2D63-825A-4BB0-9DA2-5BAD5D346DF6 @default.
- Q58088022 P1476 Q58088022-FF14B3AF-1017-4A24-96D1-508C621E2A2E @default.
- Q58088022 P2093 Q58088022-28757795-B363-44A2-BE89-4756EFB230E2 @default.
- Q58088022 P2093 Q58088022-39F01DCF-9B84-4AEA-B71E-CE400BABDA9B @default.
- Q58088022 P2093 Q58088022-7633B0A6-E4E3-486A-BCD1-5E03E3D35CA4 @default.
- Q58088022 P2093 Q58088022-8755F75D-3CC8-40A5-BDDA-29034A8C2849 @default.
- Q58088022 P2093 Q58088022-8CBED4A8-0BB4-4184-9639-4328C90CA63E @default.
- Q58088022 P2093 Q58088022-BC150537-FD9C-42FB-B1C8-56329F4090F6 @default.
- Q58088022 P2093 Q58088022-CA13AA07-B9F4-4891-9AF2-002A4208CF6D @default.
- Q58088022 P2093 Q58088022-EAD19997-47A0-48AD-BF16-60551E76EA7C @default.
- Q58088022 P2093 Q58088022-EC663E16-1E8E-421C-BB19-8F35F3D812D6 @default.
- Q58088022 P2860 Q58088022-59433FCA-AC86-43B6-AAE4-D8C6AD2E982B @default.
- Q58088022 P2860 Q58088022-86273EF0-74F1-4362-BA25-A57C94AA0D3A @default.
- Q58088022 P2860 Q58088022-932AEE9E-4B5C-4F0D-8BB8-5FCFF1DA50B4 @default.
- Q58088022 P2860 Q58088022-9C683788-4294-424E-9C53-47CF7E8615DD @default.
- Q58088022 P2860 Q58088022-DE631D2D-744D-4AA0-A3F7-4E777421F382 @default.
- Q58088022 P2860 Q58088022-EE243425-C990-4D41-9724-CE228495CF3D @default.
- Q58088022 P304 Q58088022-8D4CFB6F-376D-43B6-AA34-3F1B360CB7A2 @default.
- Q58088022 P31 Q58088022-DC483F41-C183-4208-AD60-0ACB5CCD3F83 @default.
- Q58088022 P356 Q58088022-094930C7-64D5-40EC-9D31-F9C5341F5217 @default.
- Q58088022 P407 Q58088022-50C4B2D4-8E98-4E52-8E03-E02FD82981D9 @default.
- Q58088022 P433 Q58088022-EE948B9D-3FFE-4F12-965E-17B65D5E38CC @default.
- Q58088022 P478 Q58088022-2654875A-E948-4B9E-BA10-43B4145AA442 @default.
- Q58088022 P50 Q58088022-8514884A-36A5-437B-B2EC-DBF52B19F976 @default.
- Q58088022 P577 Q58088022-FA8192B9-BB54-4770-BDB8-F401C533B9D8 @default.
- Q58088022 P698 Q58088022-BB960F8F-6C17-4939-B14A-09DDA8B181F0 @default.
- Q58088022 P921 Q58088022-6428AF56-D268-49A7-94DE-3DA8E1D056B8 @default.
- Q58088022 P932 Q58088022-0C9FAFE6-DF74-48E4-AA62-D3DEE12ADBAF @default.
- Q58088022 P356 HAEMATOL.2018.203885 @default.
- Q58088022 P698 30381302 @default.
- Q58088022 P1433 Q5638209 @default.
- Q58088022 P1476 "A phase II study of the efficacy and safety of an intensified schedule of azacitidine in intermediate-2 and high risk patients with myelodysplastic syndromes: a study by the Groupe Francophone des myelodysplasies (GFM)" @default.
- Q58088022 P2093 "Agnès Guerci-Bresler" @default.
- Q58088022 P2093 "Jacques Delaunay" @default.
- Q58088022 P2093 "Kristell Desseaux" @default.
- Q58088022 P2093 "Laurence Legros" @default.
- Q58088022 P2093 "Lionel Ades" @default.
- Q58088022 P2093 "Marie Sebert" @default.
- Q58088022 P2093 "Pascale Cony-Makhoul" @default.
- Q58088022 P2093 "Sylvie Chevret" @default.
- Q58088022 P2093 "Thosten Braun" @default.
- Q58088022 P2860 Q24563021 @default.
- Q58088022 P2860 Q33381378 @default.
- Q58088022 P2860 Q37566878 @default.
- Q58088022 P2860 Q37702336 @default.
- Q58088022 P2860 Q46102907 @default.
- Q58088022 P2860 Q58706592 @default.
- Q58088022 P304 "e131-e133" @default.
- Q58088022 P31 Q13442814 @default.
- Q58088022 P356 "10.3324/HAEMATOL.2018.203885" @default.
- Q58088022 P407 Q1860 @default.
- Q58088022 P433 "4" @default.
- Q58088022 P478 "104" @default.
- Q58088022 P50 Q30170095 @default.
- Q58088022 P577 "2018-10-31T00:00:00Z" @default.
- Q58088022 P698 "30381302" @default.
- Q58088022 P921 Q103824 @default.
- Q58088022 P932 "6442966" @default.